IGC Pharma Receivables

IGC Pharma (IGC) currently reports a receivables of $56K as of June 2026. That compares with $190K in the prior-year period — down 69.7% year over year. Use the charts on this page to explore IGC Pharma's receivables history and peer comparisons.

IGC Pharma's receivables decreased from $190K to $56K — a 69.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

IGC Pharma reported $56K in receivables as of June 2026. That compares with $190K in the prior-year period — down 69.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $56K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for IGC Pharma, and consider following IGC for alerts when major investors trade the stock.

IGC Pharma is classified in the Healthcare sector. On receivables, it currently shows $56K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IGC with unrelated industries.